GlobeNewswire Inc.··FdaFDA Approves Regeneron's Landmark Gene Therapy for Genetic Hearing Loss in Record 61 Days
FDA approves $REGN's Otarmeni, first dual AAV gene therapy for genetic hearing loss, in record 61 days under priority voucher program. 80% of patients showed improved hearing.
REGNFDA approvalrare disease